News & Trends - Pharmaceuticals
BMS’ second-generation TKI now registered to treat children with Ph+ leukaemia

Pharma News: Coping with a paediatric cancer diagnosis, including identifying the right treatment regimen, can take a significant physical and emotional toll on children and their families.
The Therapeutic Goods Administration (TGA) has expanded the indication for Bristol-Myers Squibb’s Sprycel (dasatinib) tablets to include the treatment of paediatric patients newly diagnosed with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.
Sprycel is the only second-generation tyrosine kinase inhibitor (TKI) approved for this patient population.
The efficacy of Sprycel tablets in combination with chemotherapy was evaluated in a single cohort of the Phase 2, multicentre, single-arm CA180-372 study, which included paediatric patients with newly diagnosed B-cell precursor Ph+ ALL. At three years, the study demonstrated an event-free survival (EFS) binary rate of 64.1% (95% confidence interval [CI]: 52.4 to 74.7).
Acute lymphoblastic leukaemia is characterised by chromosomal abnormalities and genetic alterations involved in the differentiation and proliferation of lymphoid precursor cells. The most common childhood cancer, ALL represents 20% of all cancers diagnosed in persons aged less than 20 years, or more than 3,000 new cases each year. Only 3% of children who have ALL have the Ph+ subtype, which means they have a chromosome alteration that results in a specific mutation of the BCR-ABL gene.
In addition to this paediatric approval, Sprycel is approved for use in children with Ph+ chronic myeloid leukaemia (CML) in chronic phase (CP).
News & Trends - Pharmaceuticals

Clinicians call for closer monitoring of patients post CAR T therapy
Australian clinicians are raising questions about whether cancer patients need closer monitoring after receiving CAR T-cell therapy. A Peter MacCallum […]
MoreNews & Trends - MedTech & Diagnostics

Next-gen surgical mesh to fill critical gap after regulatory ban
Next-generation urogynaecological surgical mesh implants are on the horizon for women suffering from pelvic organ prolapse (POP). This development aims […]
MoreNews & Trends - Pharmaceuticals

Contraceptive lawsuit against Bayer fails
The Victorian Supreme Court has dismissed a class action against Bayer for an allegedly defective contraceptive device. Justice Andrew Keogh […]
MoreNews & Trends - Pharmaceuticals

NSW Government ignored warnings since 2018: Mental health system unravels as psychiatrists quit en masse
The New South Wales Labor government’s plan to “redesign” the state’s mental health system, while excluding psychiatrists, has sparked intense […]
More